Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Files Registration Statement for Proposed Initial Public Offering
Zosano Pharma Files Registration Statement for Proposed Initial Public Offering Fremont, California, June 24, 2014 – Zosano Pharma Corporation (Zosano) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed
View HTML
Toggle Summary Zosano Pharma, Inc. to Present at the 74th American Diabetes Association (ADA) Scientific Session
CSO Dr. Peter Daddona to Share Data on Use of ZP-Glucagon Product Candidate in Healthy Volunteers
View HTML
Toggle Summary Zosano Pharma Appoints Winnie W. Tso, CPA as Chief Financial Officer
    Zosano Pharma Appoints Winnie W. Tso, CPA as Chief Financial Officer FREMONT, Calif., June 2, 2014 – Zosano Pharma, Inc ., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, today announced the appointment of Winnie
View HTML
Toggle Summary Zosano Pharma, Inc. to Present at the 3rd International Microneedle Conference
Zosano Pharma, Inc. to Present at the 3rd International Microneedle Conference Fremont, CA — May 19, 2014 — Zosano Pharma, Inc ., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced that Dr.
View HTML
Toggle Summary Zosano Pharma Enters into a License Agreement with Novo Nordisk to Deliver Semaglutide Using Zosano's Microneedle Patch System
Zosano Pharma Enters into a License Agreement with Novo Nordisk to Deliver Semaglutide Using Zosano's Microneedle Patch System Fremont, California, February 5, 2014 /PRNewswire/ — Zosano Pharma, Inc., (Zosano) announced today that it has entered into an agreement with Novo Nordisk A/S
View HTML
Toggle Summary Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer Fremont, CA — May 14, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with
View HTML
Toggle Summary Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
View HTML
Toggle Summary Zosano Pharma, Inc. Announces Key Strategic Hire
Seasoned Business Development Executive Chris Krueger Joins as Chief Business Officer
View HTML
Toggle Summary Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
Asahi Kasei Pharma Obtains Exclusive Rights in Osteoporosis in Japan, China, Korea and Taiwan (Asia)
View HTML
Toggle Summary Zosano Pharma, Inc. To Present At The 14Th Annual Drug Delivery Partnerships Meeting..
Zosano Pharma, Inc. To Present At The 14Th Annual Drug Delivery Partnerships Meeting.. Fremont, Calif. January 20, 2010 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Dr.
View HTML